Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Interventional 9 Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 2 Stomach Neoplasms 1 Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety 1 Lung Neoplasms 1 Liver Neoplasms 1 Glioma 1 Glioblastoma 1 Breast Cancer Organoids 1 Advanced Gastric Cancer 1

Interventions

Blood Specimen Collection 32 Surveys and Questionnaires 24 Radiotherapy 12 Gene Expression Profiling 12 Drug Therapy 12 Surgical Procedures, Operative 11 Bronchoscopy 10 Magnetic Resonance Spectroscopy 9 Immunotherapy 9 Immunohistochemistry 9 Tomography, X-Ray Computed 8 Specimen Handling 8 Observation 8 Amplified Fragment Length Polymorphism Analysis 8 Polymerase Chain Reaction 7 pembrolizumab 6 Psychiatric Rehabilitation 6 Interviews as Topic 6 Carboplatin 6 Thoracic Surgery, Video-Assisted 5 Reverse Transcriptase Polymerase Chain Reaction 5 Microarray Analysis 5 Liquid Biopsy 5 Chemoradiotherapy 5 Bevacizumab 5 durvalumab 4 Therapeutics 4 Paclitaxel 4 Nivolumab 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Lung Neoplasms × apatinib × Clear all

NCT03376191 2017-12-18

Apatinib in Advanced Non-squamous，NSCLC

Peking University Cancer Hospital & Institute

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡